Wealthfront Advisers LLC Bristol Myers Squibb CO Transaction History

Wealthfront Advisers LLC

$34.9 Billion
Q1 2025

A detailed history of Wealthfront Advisers LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wealthfront Advisers LLC holds 365,783 shares of BMY stock, worth $18.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

365,783

Previous 249,605 46.54%

Holding current value

$18.3 Million

Previous $14.1 Million 58.03%

% of portfolio

0.06%

Previous 0.04%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 02, 2025	BUY	$53.9 - $63.11 $6.26 Million - $7.33 Million	116,178 Added 46.54%	365,783 $22.3 Million
Q4 2024 Apr 01, 2025	BUY	$51.92 - $59.94 $11.8 Million - $13.7 Million	228,183 Added 1065.18%	249,605 $14.1 Million
Q4 2024 Feb 07, 2025	SELL	$51.92 - $59.94 $4.08 Million - $4.7 Million	-78,491 Reduced 78.56%	21,422 $1.21 Million
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $2.85 Million - $3.72 Million	71,914 Added 256.84%	99,913 $5.17 Million
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $2.09 Million - $2.75 Million	-51,933 Reduced 64.97%	27,999 $1.16 Million
Q1 2024 Apr 19, 2024	SELL	$47.98 - $54.4 $2.71 Million - $3.08 Million	-56,532 Reduced 41.43%	79,932 $4.33 Million
Q4 2023 Feb 09, 2024	SELL	$48.48 - $57.85 $319,628 - $381,405	-6,593 Reduced 4.61%	136,464 $7 Million
Q3 2023 Nov 01, 2023	SELL	$57.89 - $64.73 $2.73 Million - $3.06 Million	-47,216 Reduced 24.81%	143,057 $8.3 Million
Q2 2023 Aug 07, 2023	BUY	$63.71 - $70.74 $400,417 - $444,600	6,285 Added 3.42%	190,273 $12.2 Million
Q1 2023 Apr 28, 2023	SELL	$65.71 - $74.53 $3.98 Million - $4.52 Million	-60,632 Reduced 24.79%	183,988 $12.8 Million
Q4 2022 Feb 10, 2023	BUY	$68.48 - $81.09 $157,709 - $186,750	2,303 Added 0.95%	244,620 $17.6 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $685 - $405,407	5,276 Added 2.23%	242,317 $17.2 Million
Q2 2022 Jul 20, 2022	BUY	$72.62 - $79.98 $2.59 Million - $2.85 Million	35,663 Added 17.71%	237,041 $18.3 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $5.03 Million - $6.03 Million	81,853 Added 68.48%	201,378 $14.7 Million
Q4 2021 Jan 21, 2022	BUY	$53.63 - $62.52 $763,154 - $889,659	14,230 Added 13.51%	119,525 $7.45 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $2.04 Million - $2.38 Million	-34,393 Reduced 24.62%	105,295 $6.23 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $136,140 - $148,256	2,199 Added 1.6%	139,688 $9.33 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $522,963 - $588,179	8,813 Added 6.85%	137,489 $8.68 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $107,396 - $121,699	1,860 Added 1.47%	128,676 $7.98 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $558,391 - $618,771	9,723 Added 8.3%	126,816 $7.65 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $160,074 - $187,142	2,920 Added 2.56%	117,093 $6.89 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $735,486 - $1.07 Million	15,851 Added 16.12%	114,173 $6.36 Million
Q4 2019 Jan 21, 2020	BUY	$49.21 - $64.19 $2.62 Million - $3.42 Million	53,321 Added 118.49%	98,322 $6.31 Million
Q3 2019 Oct 15, 2019	BUY	$42.77 - $50.71 $1.06 Million - $1.26 Million	24,759 Added 122.31%	45,001 $2.28 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $182,763 - $202,096	4,096 Added 25.37%	20,242 $918,000
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $1.09 Million - $1.29 Million	-24,067 Reduced 59.85%	16,146 $770,000
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $1.96 Million - $2.54 Million	40,213 New	40,213 $2.09 Million

Others Institutions Holding BMY

# of Institutions

2,811

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $106B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthfront Advisers LLC with notifications on news.

Account

Wealthfront Advisers LLC Bristol Myers Squibb CO Transaction History